INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sage Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
Sage Therapeutics, Inc. (SAGE)
Last sage therapeutics, inc. earnings: 2/27 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sagerx.com/investor-relations
Company Research
Source: Accesswire
Impact Snapshot
Event Time:
SAGE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SAGE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SAGE alerts
High impacting Sage Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SAGE
News
- Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at Scotiabank from $17.00 to $14.00. They now have a "sector outperform" rating on the stock.MarketBeat
- Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $26.00 price target on the stock, down previously from $52.00.MarketBeat
- Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $9.00 to $8.00. They now have a "market perform" rating on the stock.MarketBeat
- Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at Truist Financial Co. from $13.00 to $8.00. They now have a "hold" rating on the stock.MarketBeat
- Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at HC Wainwright from $25.00 to $14.00. They now have a "neutral" rating on the stock.MarketBeat
SAGE
Earnings
- 10/29/24 - Miss
SAGE
Sec Filings
- 10/29/24 - Form 10-Q
- 10/29/24 - Form 8-K
- 10/21/24 - Form SC
- SAGE's page on the SEC website